KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Treasury Shares (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Treasury Shares data on record, last reported at $5.9 million in Q4 2025.

  • For Q4 2025, Treasury Shares rose 609.09% year-over-year to $5.9 million; the TTM value through Dec 2025 reached $5.9 million, up 609.09%, while the annual FY2025 figure was $5.9 million, 609.09% up from the prior year.
  • Treasury Shares reached $176.6 million in Q4 2025 per PCRX's latest filing, up from $125.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $5.9 million in Q4 2025 and bottomed at $837000.0 in Q2 2024.
  • Average Treasury Shares over 5 years is $1.6 million, with a median of $1.1 million recorded in 2023.
  • The widest YoY moves for Treasury Shares: up 602.86% in 2025, down 200.61% in 2025.
  • A 2-year view of Treasury Shares shows it stood at $25.1 million in 2024, then surged by 602.86% to $176.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $5.9 million in Q4 2025, $3.9 million in Q3 2025, and $2.0 million in Q2 2025.